$PRPH
ProPhase Labs, Inc. Stock $prph

$prph Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022350 Filed on August 12, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$24.20M	$29.10M	$47.53M
YoY Change	155.49%	219.78%	211.27%
Cost Of Revenue	$12.23M	$10.37M	$18.85M
YoY Change	122.51%	121.81%	197.38%
Gross Profit	$11.97M	$18.72M	$28.68M
YoY Change	201.06%	319.17%	221.13%
Gross Profit Margin	49.48%	64.33%	60.33%
Selling, General & Admin	$7.512M	$6.306M	$7.824M
YoY Change	26.51%	26.3%	106.98%
% of Gross Profit	62.74%	33.69%	27.28%
Research & Development	$110.0K	$28.00K	$35.00K
YoY Change	-47.12%	-69.89%	-70.83%
% of Gross Profit	0.92%	0.15%	0.12%
Depreciation & Amortization	$540.0K	$607.0K	$1.249M
YoY Change	-41.68%	28.06%	131.3%
% of Gross Profit	4.51%	3.24%	4.36%
Operating Expenses	$10.02M	$8.133M	$12.53M
YoY Change	31.43%	37.47%	62.53%
Operating Profit	$1.953M	$10.59M	$16.15M
YoY Change	-153.55%	-830.14%	1223.44%
Interest Expense	$201.0K	$201.0K	-$236.0K
YoY Change	-160.73%	-37.77%	47.5%
% of Operating Profit	10.29%	1.9%	-1.46%
Other Income/Expense, Net	$0.00	$0.00	-$76.00K
YoY Change
Pretax Income	$1.777M	$10.41M	$15.91M
YoY Change	-144.67%	-846.31%	1400.94%
Income Tax	$809.0K	$2.965M	$3.416M
% Of Pretax Income	45.53%	28.48%	21.47%
Net Earnings	$968.0K	$7.446M	$12.49M
YoY Change	-124.33%	-633.76%	1078.68%
Net Earnings / Revenue	4.0%	25.59%	26.29%
Basic Earnings Per Share	$0.06	$0.48	$0.81
Diluted Earnings Per Share	$0.06	$0.40	$666.7K
COMMON SHARES
Basic Shares Outstanding	16.01M shares	15.58K shares	15.49K shares
Diluted Shares Outstanding	20.25K shares	19.27K shares	18.74K shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.48M	$27.50M	$29.35M
YoY Change	15.82%	-24.15%	-19.06%
Cash & Equivalents	$22.80M	$23.96M	$25.81M
Short-Term Investments	$3.678M	$3.539M	$3.543M
Other Short-Term Assets	$1.105M	$1.598M	$1.831M
YoY Change	-40.33%	273.36%	195.32%
Inventory	$4.912M	$4.509M	$4.680M
Prepaid Expenses
Receivables	$37.83M	$36.67M	$36.69M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$70.33M	$70.28M	$72.56M
YoY Change	60.18%	20.14%	7.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.063M	$6.252M	$10.76M
YoY Change	-44.57%	-45.53%	-8.2%
Goodwill	$5.709M	$5.709M
YoY Change
Intangibles	$8.889M	$9.434M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.282M	$1.282M	$499.0K
YoY Change	-73.52%	-71.09%	-88.79%
Total Long-Term Assets	$27.55M	$27.67M	$27.11M
YoY Change	-4.09%	55.19%	49.04%
TOTAL ASSETS
Total Short-Term Assets	$70.33M	$70.28M	$72.56M
Total Long-Term Assets	$27.55M	$27.67M	$27.11M
Total Assets	$97.88M	$97.95M	$99.67M
YoY Change	34.76%	28.33%	16.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.545M	$4.445M	$8.204M
YoY Change	-35.46%	-37.52%	5.45%
Accrued Expenses	$328.0K	$226.0K	$3.511M
YoY Change	-94.24%	-90.03%	-28.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.69M	$16.72M	$19.77M
YoY Change	68.07%	17.98%	8.09%
LONG-TERM LIABILITIES
Long-Term Debt	$7.999M	$7.998M	$8.015M
YoY Change	-20.61%	-19.97%	-19.77%
Other Long-Term Liabilities	$5.264M	$5.069M	$4.992M
YoY Change	20.79%	14.63%	10.93%
Total Long-Term Liabilities	$13.26M	$13.07M	$13.01M
YoY Change	-8.11%	-9.36%	-10.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.69M	$16.72M	$19.77M
Total Long-Term Liabilities	$13.26M	$13.07M	$13.01M
Total Liabilities	$29.96M	$29.79M	$33.22M
YoY Change	22.94%	4.19%	1.34%
SHAREHOLDERS EQUITY
Retained Earnings	$14.20M	$13.23M
YoY Change
Common Stock	$17.00K	$16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$54.14M	$51.02M
YoY Change
Treasury Stock Shares	17.71M shares	17.35M shares
Shareholders Equity	$67.92M	$68.16M	$66.45M
YoY Change
Total Liabilities & Shareholders Equity	$97.88M	$97.95M	$99.67M
YoY Change	34.76%	28.33%	16.65%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$968.0K	$7.446M	$12.49M
YoY Change	-124.33%	-633.76%	1078.68%
Depreciation, Depletion And Amortization	$540.0K	$607.0K	$1.249M
YoY Change	-41.68%	28.06%	131.3%
Cash From Operating Activities	$2.632M	$4.821M	$20.29M
YoY Change	-147.66%	8.58%	-357.12%
INVESTING ACTIVITIES
Capital Expenditures	-$554.0K	-$674.0K	-$1.095M
YoY Change	2538.1%	119.54%	-72.14%
Acquisitions			$0.00
YoY Change
Other Investing Activities	-$116.0K	$186.0K	$5.179M
YoY Change	-96.54%	-101.27%	-277.97%
Cash From Investing Activities	-$670.0K	-$488.0K	$4.084M
YoY Change	-80.13%	-96.74%	-159.8%
FINANCING ACTIVITIES
Cash Dividend Paid			$4.646M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.122M	-6.181M	-7.222M
YoY Change		35.82%	-117.77%
NET CHANGE
Cash From Operating Activities	2.632M	4.821M	20.29M
Cash From Investing Activities	-670.0K	-488.0K	4.084M
Cash From Financing Activities	-3.122M	-6.181M	-7.222M
Net Change In Cash	-1.160M	-1.848M	17.15M
YoY Change	-86.96%	-87.73%	-33.84%
FREE CASH FLOW
Cash From Operating Activities	$2.632M	$4.821M	$20.29M
Capital Expenditures	-$554.0K	-$674.0K	-$1.095M
Free Cash Flow	$3.186M	$5.495M	$21.38M
YoY Change	-157.92%	15.76%	-639.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000868278
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	PRPH	Inventory Valuation Reserve InventoryValuationReserve		usd
	PRPH	Noncash Interest Income On Secured Promissory Note Receivable NoncashInterestIncomeOnSecuredPromissoryNoteReceivable		usd
	PRPH	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices		usd
	PRPH	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable		usd
	PRPH	Issuance Of Secured Promissory Note Receivable IssuanceOfSecuredPromissoryNoteReceivable		usd
	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	PRPH	Proceeds From Issuance Of Common Stock And Warrants From Private Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	PRPH	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion		usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	PRPH	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote		usd
	PRPH	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote		usd
CY2021Q2	PRPH	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions		shares
	PRPH	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions		shares
CY2021Q2	PRPH	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants		shares
	PRPH	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants		shares
CY2021Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-21617
	dei	Entity Registrant Name EntityRegistrantName	ProPhase Labs, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-2577138
	dei	Entity Address Address Line1 EntityAddressAddressLine1	711 Stewart Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Garden City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11530
	dei	City Area Code CityAreaCode	215
	dei	Local Phone Number LocalPhoneNumber	345-0919
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0005
	dei	Trading Symbol TradingSymbol	PRPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16006222	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23959000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8408000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3539000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8779000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1890000	usd
CY2022Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	155000	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	104000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	628000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	663000	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2430000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2034000	usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	6787000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1312000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1517000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2495000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16722000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15524000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	983000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	76000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36670000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37708000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4509000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4600000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1598000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1496000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	70275000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61317000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6252000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5947000	usd
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	167000	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	460000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4234000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4402000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9434000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10852000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	5709000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	594000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1282000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	608000	usd
CY2022Q2	us-gaap	Assets Assets	97947000	usd
CY2021Q4	us-gaap	Assets Assets	89295000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4445000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7026000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	760000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	905000	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	44000	usd
CY2022Q2	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	7998000	usd
CY2021Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	9996000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4086000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4198000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13067000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15143000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	29789000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30667000	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15722827	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15485900	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106162000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104552000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	13231000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2642000	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	17352419	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	16818846	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	51015000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48407000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-236000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-175000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	68158000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58628000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97947000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89295000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29092000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9142000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76623000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24413000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10372000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4676000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29226000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11020000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	18720000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	4466000	usd
	us-gaap	Gross Profit GrossProfit	47397000	usd
	us-gaap	Gross Profit GrossProfit	13393000	usd
CY2022Q2	PRPH	Diagnostic Expenses DiagnosticExpenses	1799000	usd
CY2021Q2	PRPH	Diagnostic Expenses DiagnosticExpenses	830000	usd
	PRPH	Diagnostic Expenses DiagnosticExpenses	6471000	usd
	PRPH	Diagnostic Expenses DiagnosticExpenses	4639000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6306000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4993000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14130000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8775000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	208000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8133000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5916000	usd
	us-gaap	Operating Expenses OperatingExpenses	20664000	usd
	us-gaap	Operating Expenses OperatingExpenses	13622000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	10587000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1450000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	26733000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-229000	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	25000	usd
CY2021Q2	us-gaap	Interest Income Other InterestIncomeOther	214000	usd
	us-gaap	Interest Income Other InterestIncomeOther	98000	usd
	us-gaap	Interest Income Other InterestIncomeOther	301000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	201000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	323000	usd
	us-gaap	Interest Expense InterestExpense	434000	usd
	us-gaap	Interest Expense InterestExpense	574000	usd
CY2021Q2	PRPH	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	164000	usd
	PRPH	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	-76000	usd
	PRPH	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	164000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10411000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1395000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	26321000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-338000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2965000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6381000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	7446000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1395000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	19940000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-338000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	7446000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1395000	usd
	us-gaap	Net Income Loss NetIncomeLoss	19940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-338000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-98000	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-67000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-61000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-78000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7348000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1462000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19879000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-416000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.48
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15576	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15154	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15531	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14860	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19272	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15154	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18964	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14860	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	66445000	usd
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	4705000	usd
CY2022Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-7000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-98000	usd
CY2022Q2	PRPH	Treasuer Stock Repurchased During Period Value TreasuerStockRepurchasedDuringPeriodValue	-1458000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	528000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	7446000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	68158000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	52665000	usd
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	4546000	usd
CY2021Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-5000	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-67000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1076000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1395000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	47733000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58628000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	600000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	9351000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1150000	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1458000	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-186000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-61000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1010000	usd
	us-gaap	Net Income Loss NetIncomeLoss	19940000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	68158000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	10556000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35135000	usd
	PRPH	Issuance Of Common Stock And Warrants IssuanceOfCommonStockAndWarrants	5500000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	4546000	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-7000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-78000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1504000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-338000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	47733000	usd
	us-gaap	Net Income Loss NetIncomeLoss	19940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-338000	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-186000	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-7000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2516000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1118000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	168000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	167000	usd
	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	-74000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1010000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1504000	usd
	PRPH	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	-76000	usd
	PRPH	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	164000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1988000	usd
	PRPH	Inventory Valuation Reserve InventoryValuationReserve	25000	usd
	PRPH	Noncash Interest Income On Secured Promissory Note Receivable NoncashInterestIncomeOnSecuredPromissoryNoteReceivable	315000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	941000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3466000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-66000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12130000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-104000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2434000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	594000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	674000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	8000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2583000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3343000	usd
	PRPH	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	-1130000	usd
	PRPH	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances	51000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	474000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-147000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	205000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5475000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-978000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	4190000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25108000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3450000	usd
	PRPH	Issuance Of Secured Promissory Note Receivable IssuanceOfSecuredPromissoryNoteReceivable	1000000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	607000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16841000	usd
	PRPH	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	5600000	usd
	PRPH	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	300000	usd
	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	372000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1769000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4237000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3596000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21778000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	35135000	usd
	PRPH	Proceeds From Issuance Of Common Stock And Warrants From Private Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering	5500000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1444000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1150000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	9351000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	4546000	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1458000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13403000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36089000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15301000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10861000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8658000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6816000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23959000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17677000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1500000	usd
	us-gaap	Interest Paid Net InterestPaidNet	441000	usd
	us-gaap	Interest Paid Net InterestPaidNet	500000	usd
	PRPH	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	-600000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	61000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	78000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	123000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3539000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8954000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3600000	usd
	PRPH	Percentage Of Revenue Services PercentageOfRevenueServices	0.49	pure
	PRPH	Percentage Of Revenue Services PercentageOfRevenueServices	0.79	pure
	us-gaap	Risks And Uncertainties In Entitys Business RisksAndUncertaintiesInEntitysBusiness	We continue to perform limited testing for uninsured persons and are incurring the accompanying costs. However, as a result of the suspension of the HRSA uninsured program, we did not recognize any revenue related to COVID-19 testing that we performed for uninsured individuals from March 23, 2022 through June 30, 2022
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25100000	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zFsMbyLAjok1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z4Ly9OSjs0K4">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	192000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8779000	usd
	PRPH	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	-76000	usd
CY2022Q2	PRPH	Trade Accounts Receivable TradeAccountsReceivable	35793000	usd
CY2021Q4	PRPH	Trade Accounts Receivable TradeAccountsReceivable	18520000	usd
CY2022Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	6766000	usd
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	23089000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	42559000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	41609000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5889000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3901000	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	36670000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	37708000	usd
CY2022Q2	PRPH	Inventory Lab Material InventoryLabMaterial	2122000	usd
CY2021Q4	PRPH	Inventory Lab Material InventoryLabMaterial	2989000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1721000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1514000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	676000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	260000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	421000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	272000	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	4940000	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	5035000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	431000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	435000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4509000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4600000	usd
	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment including lab equipment - three to seven years; computer equipment and software - three to five years; and furniture and fixtures - five years
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zrYfyXIjlYTf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zSLweYQt3yZg">Concentration of Financial Risks</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2022, our cash and cash equivalents and restricted cash balance was $<span id="xdx_90B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20220630_ztYyvhMY2oj" title="Cash and cash equivalents and restricted cash balance">24.0</span> million. Of the total bank balance, $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20220630_z2GSuZPYuPNa" title="Federal depository insurance">0.9</span> million was covered by federal depository insurance and $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20220630_zIuljpSbespb" title="Uninsured">23.1</span> million was uninsured at June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depends on information provided to the payors and meeting their requirements for reimbursement.</span></p>
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24000000.0	usd
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	900000	usd
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	23100000	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	3539000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	8855000	usd
CY2022Q2	PRPH	Breakage Revenue BreakageRevenue	300000	usd
	PRPH	Breakage Revenue BreakageRevenue	400000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2900000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	3200000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	2700000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3413000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2939000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12297000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12297000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2863000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1445000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9434000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10852000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	709000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	109000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	207000000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29092000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9142000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76623000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24413000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	208000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	960000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1585000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1222000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1222000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	890000	usd
CY2022Q2	PRPH	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	3555000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9434000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13824000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12830000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7572000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6883000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6252000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5947000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	607000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	474000	usd
	us-gaap	Depreciation Depreciation	1098000	usd
	us-gaap	Depreciation Depreciation	900000	usd
CY2022Q1	us-gaap	Cash Cash	1440548	usd
CY2022Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1400000	usd
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	40548	usd
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.75
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1150000	usd
CY2022Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2590548	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4600000	usd
CY2022Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4700000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5110000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20820000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.44
	PRPH	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Granted Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageRemainingContractualTerm2	P7Y
	PRPH	Stock Issued During Period Shares Stock Options Exercised Gross StockIssuedDuringPeriodSharesStockOptionsExercisedGross	570000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.66
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.87
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4920000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.30
	PRPH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	46159000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3662000	shares
CY2022Q2	PRPH	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercise Weighted Average Exercisable Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExerciseWeightedAverageExercisablePrice	2.31
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y3M18D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	37972000	usd
CY2022Q2	us-gaap	Share Price SharePrice	6.74
CY2021Q2	us-gaap	Share Price SharePrice	9.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.83	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.030	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	236927	shares
	PRPH	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Return Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReturnOfShares	333573	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4920000	shares
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1595785	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3821000	usd
CY2022Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	849000	usd
CY2021Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	1283000	usd
CY2022Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	47000	usd
CY2021Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	23000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	99000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	35000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2424	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0802	pure
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	81000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	514000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	226000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	300000	usd
CY2022Q2	PRPH	Accrued Return AccruedReturn	309000	usd
CY2021Q4	PRPH	Accrued Return AccruedReturn	338000	usd
CY2022Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	52000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	60000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1517000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2495000	usd
CY2022Q2	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	738000	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	1375000	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1375000	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1375000	usd
CY2022Q2	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1375000	usd
CY2022Q2	us-gaap	Contractual Obligation ContractualObligation	6238000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
	us-gaap	Payments For Rent PaymentsForRent	11290	usd
	PRPH	Gradual Rental Rate GradualRentalRate	0.0275	pure
CY2022Q2	us-gaap	Prepaid Rent PrepaidRent	14026	usd
	PRPH	Construction Allowance ConstructionAllowance	203220	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4700000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4200000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	204000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	204000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	408000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	408000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	204000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	204000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	408000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	408000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	204000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	204000	usd
	us-gaap	Lease Cost LeaseCost	408000	usd
	us-gaap	Lease Cost LeaseCost	408000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	387000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	36000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y10M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1000	pure
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1000	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	387000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	738000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	747000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	768000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	783000	usd
CY2022Q2	PRPH	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	3876000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7299000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2585000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4714000	usd
CY2021Q4	us-gaap	Secured Debt SecuredDebt	0	usd
CY2022Q2	us-gaap	Revenues Revenues	29100000	usd
CY2021Q2	us-gaap	Revenues Revenues	9100000	usd
	us-gaap	Revenues Revenues	76600000	usd
	us-gaap	Revenues Revenues	24400000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29092000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9142000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76623000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	743000	usd
CY2022Q2	PRPH	Operating And Other Expenses OperatingAndOtherExpenses	7114000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24413000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10372000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4676000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29226000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11020000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1195000	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	395000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371000	usd
CY2021Q2	PRPH	Operating And Other Expenses OperatingAndOtherExpenses	5466000	usd
	PRPH	Operating And Other Expenses OperatingAndOtherExpenses	18705000	usd
	PRPH	Operating And Other Expenses OperatingAndOtherExpenses	12988000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10411000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1395000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	26321000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-338000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2965000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6381000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	7446000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1395000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	19940000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-338000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	7446000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1395000	usd
	us-gaap	Net Income Loss NetIncomeLoss	19940000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-338000	usd
CY2022Q2	us-gaap	Assets Assets	97947000	usd
CY2021Q4	us-gaap	Assets Assets	89295000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7446000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1395000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	19940000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-338000	usd
CY2022Q2	PRPH	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	200000	usd
	PRPH	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	432000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7646000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1395000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	20372000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-338000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15576	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15154	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15531	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14860	shares
CY2022Q2	PRPH	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	2635	shares
	PRPH	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	2389	shares
CY2022Q2	PRPH	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	261	shares
	PRPH	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	244	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	800	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	800	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19272	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15154	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18964	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14860	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	730000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5283000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	730000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5283000	shares
	us-gaap	Salaries And Wages SalariesAndWages	110000	usd
	us-gaap	Salaries And Wages SalariesAndWages	84000	usd

Files In Submission

Name	View Source	Status
0001493152-22-022350-index-headers.html	Edgar Link	pending
0001493152-22-022350-index.html	Edgar Link	pending
0001493152-22-022350.txt	Edgar Link	pending
0001493152-22-022350-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prph-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
prph-20220630_cal.xml	Edgar Link	unprocessable
prph-20220630_def.xml	Edgar Link	unprocessable
prph-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prph-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRPH
ProPhase Labs, Inc. Stock $prph

2022 Q3 Form 10-Q Financial Statement

#000149315222022350 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH ProPhase Labs, Inc. Stock $prph

2022 Q3 Form 10-Q Financial Statement

#000149315222022350 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH
ProPhase Labs, Inc. Stock $prph